David Y Zhang, MD, PhD
- PROFESSOR | Pathology
- PROFESSOR | Oncological Sciences
- ASSOCIATE PROFESSOR | Preventive Medicine
Research Topics:Apoptosis/Cell Death, Cancer, Cell Cycle, Drug Design and Discovery, Molecular Biology, Nanotechnology, Pathology, Proteomics
Molecular Genetic Pathology
Anatomic & Clinical Pathology
Multi-Disciplinary Training AreaClinical Research Education Program [CLR]
MD, Norman Bethune Univ of Medical Sciences
MPH, Mount Sinai School of Medicine
PhD, NYU School of Medicine
Residency, Pathology, Mount Sinai Hospital
Residency, Occupational Medicine, Mount Sinai Hospital
Fellowship, Clinical Microbio, Mount Sinai Hospital
Fellowship, Cytopathology, Mount Sinai Hospital
Anatomic and Clinical Pathology, Cytopathology, Molecular Genetic Pathology, Preventive Medicine (Occupational Medicine)
Specific Clinical/Research Interest:
Clinical Interest: Providing molecular diagnostic tests in the areas of cancer prognosis and therapy, pharmacogenetics, hematologic disorders,and infectious diseases.
Interest: Molecular cancer biology with focus on cancer biomarker discovery and
technology development including genomics and proteomics for cancer diagnosis
Current Students: Xiufen Liu, Wei Li, Wuhan Hui
Postdoctoral Fellows: Weihua Tong MD, PhD
Research Personnel: Fei Ye PhD, Clinical Assistant Professor; Josephine Wu DDS, JD, Assistant professor
Summary of Research Studies:
We developed a signal transduction pathway-focused proteomic method, termed PROTEIN PATHWAY ARRAY (PPA), which can be used to globally screen the signaling proteins and their activation. With the assistance of computation, we are able to identify key node, hubs, pathways and signaling network that controls cell proliferation, apoptosis, angiogenesis, necrosis, etc. This method has been used to identify novel candidate proteins as cancer biomarkers for diagnosis and prognosis and/or as targets for cancer treatment. We also invented several DNA amplification technologies, including the rolling circle amplification (RCA), isothermal ramification amplification assay (RAM) and hybridization signal amplification (HSAM). These technologies have been granted by the US Patent Office and licensed to Hamilton Thorne Biosciences, a biotechnology company based in Boston. RAM, unlike conventional polymerase chain reaction (PCR), can amplify DNA, RNA and protein without the use of thermocycling. It is extremely sensitive and can detect as few as 10 molecules. HSAM is another signal amplification technology based on the principles of nucleic acid hybridization and specific ligand interaction. This technology is simple and sensitive to identify DNA/RNA targets and proteins and can be apply to in situ amplification, DNA arrays, and proteomics.
Cheng L, Zhang DY, editors. Essentials of Molecular Genetic Pathology (2007). New York, Humana/Springer Press;.
Wang H, Huang M, Zhang DY, Zhang F. Global profiling of signaling networks: study of breast cancer stem cells and potential regulation. The oncologist 2011; 16(7).
Wang H, Gillis A, Zhao C, Lee E, Wu J, Zhang F, Ye F, Zhang DY. Crocidolite asbestos-induced signal pathway dysregulation in mesothelial cells. Mutation research 2011 Aug; 723(2).
Wang D, Ye F, Sun Y, Li W, Liu H, Jiang J, Zhang Y, Liu C, Tong W, Gao L, Sun Y, Zhang W, Seetoe T, Lee P, Suo J, Zhang DY. Protein signatures for classification and prognosis of gastric cancer a signaling pathway-based approach. The American journal of pathology 2011 Oct; 179(4).
Zhang DY, Ye F, Gao L, Liu X, Zhao X, Che Y, Wang H, Wang L, Wu J, Song D, Liu W, Xu H, Jiang B, Zhang W, Wang J, Lee P. Proteomics, pathway array and signaling network-based medicine in cancer. Cell division 2009; 4.
Yi J, Zhang W, Zhang DY. Molecular Zipper: a fluorescent probe for real-time isothermal DNA amplification. Nucleic acids research 2006; 34(11).
Zhang D, Wu J, Ye F, Feng T, Lee I, Yin B. Amplification of circularizable probes for the detection of target nucleic acids and proteins. Clinica chimica acta; international journal of clinical chemistry 2006 Jan; 363(1-2).